Vidar Ormaasen

1.5k citations

27 papers · 427 indexed · h-index 15

Impact in

Virology top 5%
- HIV Research and Treatment
Infectious Diseases top 5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Infectious Encephalopathies and Encephalitis

Papers in ⓘ

Virology 14
- HIV Research and Treatment 14
Infectious Diseases 22
- HIV/AIDS drug development and treatment 16
- HIV/AIDS Research and Interventions 12
- Infectious Encephalopathies and Encephalitis 4

Co-authors: Magnus Gisslén (7 shared papers)Leo Flamholc (6 shared papers)Anne‐Marte Bakken Kran (5 shared papers)Anders Sönnerborg (5 shared papers)Oona Dunlop (5 shared papers)Johan N. Bruun (8 shared papers)Leiv Sandvik (5 shared papers)Filip Josephson (3 shared papers)
Journals: AIDS (2 papers)The AAPS Journal (2 papers)European Journal of Clinical Pharmacology (2 papers)Scientific Reports (1 paper)HIV Medicine (1 paper)
Partner nations: Norway Sweden United Kingdom

In The Last Decade

Vidar Ormaasen

26 papers receiving 420 citations

Peers

Countries citing papers authored by Vidar Ormaasen

Since Specialization

Citations

This map shows the geographic impact of Vidar Ormaasen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vidar Ormaasen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vidar Ormaasen more than expected).

Fields of papers citing papers by Vidar Ormaasen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vidar Ormaasen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vidar Ormaasen. The network helps show where Vidar Ormaasen may publish in the future.

Co-authors

The 25 scholars most cited alongside Vidar Ormaasen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vidar Ormaasen Line = papers co-authored together Vidar Ormaasen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels European Journal of Clinical Pharmacology ·Filip Josephson, Leif Bertilsson, Ylva Böttiger, Leo Flamholc, Magnus Gisslén, Vidar Ormaasen, Anders Sönnerborg, Ulf Diczfalusy	2008	54
2	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus–Infected Patients with Very Low CD4 Cell Counts The Journal of Infectious Diseases ·Veronica Miller, Andrew Phillips, Bonaventura Clotet, Amanda Mocroft, Bruno Ledergerber, Ole Kirk, Vidar Ormaasen, Panagiotis Gargalianos‐Kakolyris, Stefano Vella, Jens Lundgren, (unknown)	2002	52
3	Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment AIDS ·Dag Kvale, Vidar Ormaasen, Anne‐Marte Bakken Kran, C. Christian Johansson, Pål Aukrust, Einar Martin Aandahl, Stig S. Frøland, Kjetil Taskén	2006	27
4	Deteriorating renal function and clinical outcomes in HIV-positive persons AIDS ·Amanda Mocroft, Lene Ryom, Josip Begovać, Antonella d’Arminio Monforte, Anne Vassilenko, José M. Gatell, Éric Florence, Vidar Ormaasen, Ole Kirk, Jens Lundgren	2013	25
5	High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections Journal of Neuroinflammation ·Else Quist‐Paulsen, Pål Aukrust, Anne‐Marte Bakken Kran, Oona Dunlop, Vidar Ormaasen, Birgitte Stiksrud, Øivind Midttun, Thor Ueland, Per Magne Ueland, Tom Eirik Mollnes, Anne Ma Dyrhol‐Riise	2018	24
6	Infectious encephalitis: A description of a Norwegian cohort Scandinavian Journal of Infectious Diseases ·Else Quist‐Paulsen, Anne‐Marte Bakken Kran, Oona Dunlop, John Wilson, Vidar Ormaasen	2012	22
7	Fatal subarachnoidal haemorrhage in a Norwegian traveller with dengue virus infection Scandinavian Journal of Infectious Diseases ·Mogens Jensenius, Dag Berild, Vidar Ormaasen, Jan Mæhlen, Gunnel Lindegren, Kerstin I. Falk	2006	22
8	Immunoglobulin Levels Amongst Persons with and without Human Immunodeficiency Virus Type 1 Infection in Uganda and Norway Scandinavian Journal of Immunology ·Eric Lugada, Jonathan Mermin, (unknown), Frank Kaharuza, R. G. Downing, Nina Langeland, Vidar Ormaasen, Johan N. Bruun, Anna Colletar Awor, Elling Ulvestad	2004	21
9	Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital Journal of Antimicrobial Chemotherapy ·Clara Bratholm, Asgeir Johannessen, Ezra Naman, Svein Gunnar Gundersen, Sokoine Kivuyo, Mona Holberg‐Petersen, Vidar Ormaasen, Johan N. Bruun	2010	20
10	The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients European Journal of Clinical Pharmacology ·Filip Josephson, Maria C. H. Andersson, Leo Flamholc, Magnus Gisslén, Lars Hagberg, Vidar Ormaasen, Anders Sönnerborg, Jan Vesterbacka, Ylva Böttiger	2009	16
11	An algorithm‐based genotypic resistance score is associated with clinical outcome in HIV‐1‐infected adults on antiretroviral therapy HIV Medicine ·Vidar Ormaasen, Leiv Sandvik, Birgitta Åsjö, Mona Holberg‐Petersen, PI Gaarder, JN Bruun	2004	15
12	HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population Scandinavian Journal of Infectious Diseases ·Vidar Ormaasen, Leiv Sandvik, Susanne Dudman, Johan N. Bruun	2006	15
13	Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naïve HIV-1–Infected Patients AIDS Research and Human Retroviruses ·Arvid Edén, Lars‐Magnus Andersson, Örjan Andersson, Leo Flamholc, Filip Josephson, Staffan Nilsson, Vidar Ormaasen, Veronica Svedhem, Christer Säll, Anders Sönnerborg, Petra Tunbäck, Magnus Gisslén	2010	14
14	To what extent can clinical characteristics be used to distinguish encephalitis from encephalopathy of other causes? Results from a prospective observational study BMC Infectious Diseases ·Else Quist‐Paulsen, Anne‐Marte Bakken Kran, Elisabeth S. Lindland, Katrine Ellefsen, Leiv Sandvik, Oona Dunlop, Vidar Ormaasen	2019	14
15	HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania Antiviral Therapy ·Asgeir Johannessen, Mona Holberg‐Petersen, Gunilla Lövgaarden, Ezra Naman, Vidar Ormaasen, Mecky Matee, Svein Gunnar Gundersen, Johan N. Bruun	2010	14
16	Encephalitis and aseptic meningitis: short-term and long-term outcome, quality of life and neuropsychological functioning Scientific Reports ·Else Quist‐Paulsen, Vidar Ormaasen, Anne‐Marte Bakken Kran, Oona Dunlop, Per Magne Ueland, Thor Ueland, Randi Eikeland, Pål Aukrust, Tonje Haug Nordenmark	2019	13
17	Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial Scandinavian Journal of Infectious Diseases ·Lars‐Magnus Andersson, Jan Vesterbacka, Anders Blaxhult, Leo Flamholc, Staffan Nilsson, Vidar Ormaasen, Anders Sönnerborg, Magnus Gisslén	2013	13
18	Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy The AAPS Journal ·Dinko Rekić, Oskar Clewe, Daniel Röshammar, Leo Flamholc, Anders Sönnerborg, Vidar Ormaasen, Magnus Gisslén, Angela Äbelö, Michael Ashton	2011	11
19	Prognostic Value of Changes in CD4 Count and HIV RNA During the First Six Months on Highly Active Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection Scandinavian Journal of Infectious Diseases ·Vidar Ormaasen, Johan N. Bruun, Leiv Sandvik, Mona Holberg‐Petersen, Per Ivar Gaarder	2003	8
20	Amnesia Following Herpes Simplex Encephalitis: Diffusion-Tensor Imaging Uncovers Reduced Integrity of Normal-appearing White Matter Radiology ·Håkon Grydeland, Kristine B. Walhovd, Lars T. Westlye, Paulina Due‐Tønnessen, Vidar Ormaasen, Øyvind Sundseth, Anders M. Fjell	2010	7

About Vidar Ormaasen

Vidar Ormaasen is a scholar working on Virology, Infectious Diseases, Biological Psychiatry, Emergency Medicine and Neurology, having authored 27 papers that have together received 427 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (16 papers), HIV Research and Treatment (14 papers), HIV/AIDS Research and Interventions (12 papers), HIV-related health complications and treatments (4 papers), Infectious Encephalopathies and Encephalitis (4 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers), Autoimmune Neurological Disorders and Treatments (3 papers) and Herpesvirus Infections and Treatments (3 papers). The work is most often cited by research in Virology (175 citations), Infectious Diseases (273 citations), Emergency Medicine (76 citations), Biological Psychiatry (17 citations) and Pharmacology (42 citations). Vidar Ormaasen has collaborated with scholars based in Norway, Sweden and United Kingdom. Frequent co-authors include Magnus Gisslén, Leo Flamholc, Anne‐Marte Bakken Kran, Anders Sönnerborg, Oona Dunlop, Johan N. Bruun, Leiv Sandvik, Filip Josephson, Else Quist‐Paulsen and Ylva Böttiger. Their work appears in journals such as AIDS, The AAPS Journal, European Journal of Clinical Pharmacology, Scientific Reports and HIV Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact